EUVIMEDEUVIMED entdecken
Crossref

Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy

Jingjing Yang, Kaiyong Yang, Shiyu Du, Wen Luo, Chao Wang, Hongmei Liu, Kunguo Liu, Zhibin Zhang, Yanfeng Gao, Xin Han, Yujun Song iD

Angewandte Chemie International Edition · 11.09.2023 · 62 (37)

DOI: 10.1002/anie.202306863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 03.08.2023. Verfasst von Jingjing Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chin…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, State Key Laboratory of Analytical Chemistry for Life Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR system‐assisted immunotherapy is an attractive option in cancer therapy. However, its efficacy is still less than expected due to the limitations in delivering the CRISPR system to target cancer cells. Here, we report a new CRISPR/Cas9 tumor‐targeting delivery strategy based on bioorthogonal reactions for dual‐targeted cancer immunotherapy. First, selective in vivo metabolic labeling of cancer and activation of the cGAS‐STING pathway was achieved simultaneously through tumor microenvironment (TME)‐biodegradable hollow manganese dioxide (H‐MnO 2 ) nano‐platform. Subsequently, CRISPR/Cas9 system‐loaded liposome was accumulated within the modified tumor tissue through in vivo click chemistry, resulting in the loss of protein tyrosine phosphatase N2 (PTPN2) and further sensitizing tumors to immunotherapy. Overall, our strategy provides a modular platform for precise gene editing in vivo and exhibits potent antitumor response by boosting innate and adaptive antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsHumansManganese CompoundsOxidesImmunotherapyGene EditingTumor Microenvironment

Stichwörter der Autor:innen

CRISPR/CasGene EditingImmunotherapyPtpn2 DeletioncGAS/STING Pathway

Substanzen

Manganese CompoundsOxides

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chine…
  • College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Xianlin Road 163, Nanjing, 21002…
  • School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, 225002, China.
  • Academy of National Food and Strategic Reserves Administration, No. 11 Baiwanzhuang Str, Xicheng District, Beijing, 100037, China.

ORCID-Profile: Yujun Song

Förderung

  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • State Key Laboratory of Analytical Chemistry for Life Science

Zitieren

APA

Yang, J., Yang, K., Du, S., Luo, W., Wang, C., Liu, H., Liu, K., Zhang, Z., Gao, Y., Han, X., & Song, Y. (2023). Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy. Angewandte Chemie International Edition, 62(37). https://doi.org/10.1002/anie.202306863

Vancouver

Yang J, Yang K, Du S, Luo W, Wang C, Liu H, et al. Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy. Angewandte Chemie International Edition. 2023;62(37). doi:10.1002/anie.202306863

BibTeX
@article{Yang2023,
  author = {Yang, Jingjing and Yang, Kaiyong and Du, Shiyu and Luo, Wen and Wang, Chao and Liu, Hongmei and Liu, Kunguo and Zhang, Zhibin and Gao, Yanfeng and Han, Xin and Song, Yujun},
  title = {Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy},
  journal = {Angewandte Chemie International Edition},
  year = {2023},
  volume = {62},
  number = {37},
  doi = {10.1002/anie.202306863}
}
Kostenlos starten →